Association between Dietary Vitamin E Intake and Esophageal Cancer Risk: An Updated Meta-Analysis

Lingling Cui *, Li Li, Yalan Tian, Fan Xu and Tianyi Qiao

Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; lili01060209@163.com (L.L.); lhk0829@163.com (Y.T.); 18790670831@163.com (F.X.); 13253610181@163.com (T.Q.)

* Correspondence: cll@zzu.edu.cn; Tel.: +86-3865-2600

Received: 18 May 2018; Accepted: 18 June 2018; Published: 21 June 2018

Abstract: Epidemiological studies have provided ambiguous evidence on the association between vitamin E and esophageal cancer risk. To resolve this controversy, we performed this meta-analysis. The literature was searched by using Excerpta Medica Database (EMBASE), PubMed, the Web of Science, and the Cochrane Library from the inception to April 2018. A random effect model was utilized to calculate the odds ratio (OR) with the 95% confidence interval (95% CI). Twelve articles reporting 14 studies involving 3013 cases and 11,384 non-cases were included. By comparing the highest category with the lowest category of dietary vitamin E intake, we found that dietary vitamin E intake was inversely related to esophageal cancer risk (OR = 0.47, 95% CI: 0.36–0.60). Subgroup analysis revealed that dietary vitamin E intake had a significantly negative association with both the esophageal squamous cell carcinoma risk (OR = 0.29, 95% CI: 0.18–0.44) and the esophageal adenocarcinoma risk (OR = 0.66, 95% CI: 0.49–0.88). No study significantly affected the findings in the sensitivity analysis. Publication bias was discovered, however, the OR (95% CI) remained unchanged after the trim-and-fill analysis. This meta-analysis showed that the higher dietary vitamin E intake is associated with a lower esophageal cancer risk. However, the association still needs to be upheld by more large-scaled randomized controlled trials and prospective studies.

Keywords: dietary; vitamin E; tocopherol; esophageal cancer; meta-analysis

1. Introduction

Esophageal cancer is the eighth most common type of cancer worldwide. With an estimated 455,784 new cases and approximately 400, 169 deaths in 2012, esophageal cancer is the sixth most common cause of death from cancer. The highest mortality rates of esophageal cancer are in Eastern Asia (14.1 per 100,000) and Southern Africa (12.8 per 100,000) in men and in Eastern Asia (7.3 per 100,000) and Southern Africa (6.2 per 100,000) in women [1]. There are two main pathological subtypes of esophageal cancer: esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). EAC is widespread in the western world, whereas ESCC is the predominant type for esophageal cancer worldwide [2,3]. EAC tends to occur in the distal esophagus from Barrett’s esophagus [3]. ESCC, however, has a tendency to occur in the squamous epithelium undergoing inflammatory changes [3]. Many possible factors cause esophageal cancer, including smoking, drinking, hot tea, red meat, poor oral health, low intake of fresh fruit and vegetables, low socioeconomic status, high body mass index (BMI), and Helicobacter pylori (H. pylori) infection [3,4]. Owing to the poor survival rate for esophageal cancer (overall ratio of mortality to incidence was 0.88) [1], nutritional prevention has been increasingly focused by scholars in recent decades.

Vitamin E is a fat-soluble vitamin including eight homologues: four tocopherols (α-tocopherol (T), β-T, γ-T, δ-T) and four tocotrienols (α-tocotrienol (TT), β-TT, γ-TT, δ-TT). α-tocopherol, the major
Nutrients 2018, 10, 801

active form of vitamin E with strong antioxidant properties, can eliminate reactive oxygen species, inhibit carcinogenesis and tumor growth, and stimulate cancer cell apoptosis [5–8]. Accordingly, it was presumed that higher dietary vitamin E intake was inversely associated with the risk of esophageal cancer. Up to now, many epidemiological studies have explored the association between vitamin E intake and the esophageal cancer risk. Some case–control studies reported that dietary vitamin E intake was inversely related with esophageal cancer risk [8–12], however, some studies were unable to find the inverse association [13,14]. To solve the divergence mentioned above, we performed this meta-analysis to systematically and quantitatively estimate the association between dietary vitamin E intake and esophageal cancer risk based on the relevant literature.

2. Materials and Methods

2.1. Search Strategy

Two investigators independently searched the electronic databases of Excerpta Medica Database (EMBASE), PubMed, the Web of Science, and the Cochrane Library up to April 2018. The following terms were used for the search: “(Vitamin E or tocopherol or tocopherols or α-Tocopherol or γ-Tocopherol or β-Tocopherol or δ-Tocopherol) and (esophageal or esophagus or oesophageal or oesophagus) and (neoplasm or neoplasms or cancer or cancers or carcinoma or tumor or tumors or tumour or tumours)”. In addition, the lists of references and reviews were also searched as potential supplements. The irrelevant articles were excluded by viewing the title, abstract, and full text. If one full-text could not be viewed or downloaded from the aforementioned electronic databases, we attempted to get the full-text by searching the online academic search and full-text delivery system or by contacting the corresponding author.

2.2. Study Selection

The inclusion criteria were the following terms: (1) cohort or randomized controlled trial (RCT) or case–control studies; (2) cases were diagnosed with esophageal cancer; (3) the dietary vitamin E intake was assessed by food frequency questionnaire and the vitamin E food composition database; (4) odds ratio (OR), hazard ratio (HR), or relative risk (RR) with their corresponding 95% confidence interval (CI) were reported or calculated; (5) detailed sample sizes were available; (6) articles were published in English; (7) as to dose–response analysis, the OR/HR/RR with 95% CI for esophageal cancer and person-years or the number of cases for each quantitative category of dietary vitamin E intake were available.

The following exclusion criteria were also considered: (1) nonhuman studies, review articles, letters to editor, or case reports; (2) cross-sectional studies; (3) studies where only vitamin E supplement use or serum vitamin E level were reported instead of dietary vitamin E intake; (4) studies where OR/RR/HR with 95% CI were not reported or calculated; (5) studies where detailed sample sizes were not reported.

2.3. Data Extraction and Quality Assessment

All data were extracted independently by two researchers and the ambiguities were resolved by a third investigator. The following information was extracted: (1) the last name of the first author; (2) publication year; (3) gender and age of participants; (4) the study period; (5) country; (6) source of control; (7) study design; (8) method of identifying cases; (9) the number of cases and non-cases; (10) assessment method of dietary vitamin E intake; (11) RR, OR, or HR (95% CI) for the maximizing adjusted model for the highest versus the lowest dietary vitamin E intake; (12) the adjusted covariance for multivariate analysis.

We assessed the methodological quality of included articles according to the instruction of Newcastle–Ottawa Scale (NOS) [15], including three quality parameters: selection, comparability, and
outcome (for prospective studies) or exposure (for case–control studies). For the NOS score, one star means one point.

2.4. Statistical Analysis

OR, HR, and RR were used for analyzing dichotomous data in one meta-analysis. OR was a fair approximation of RR when the incidence of an event was rare. Since esophageal cancer incidence is small, OR and HR are theoretically similar to RR [16]. Therefore, OR was used only for pooling the dichotomous data in this meta-analysis. The heterogeneity among studies was estimated by Cochrane’s Q and $I^2$ statistics. Generally, the 25%, 50%, and 75% of $I^2$ values refer to low, moderate and high levels of heterogeneity, respectively [17]. If $I^2 > 50\%$ and $p < 0.05$, a random-effect model was applied to pool OR (95% CI), if not, a fixed-effect model was used for pooling OR (95% CI) [18].

We performed meta-regression and subgroup analysis to explore the potential source of heterogeneity based on pathological type (ESCC, EAC, or mixed subtype), geographical distribution (America, Europe, or others), study type (case-control, or cohort study), source of control (population-based or hospital-based), sample size ($\geq 500$ or <500), the method for identifying esophageal cancer cases (pathological diagnoses or cancer registries), dietary vitamin E assessment method (validated food frequency questionnaire (FFQ) or unvalidated FFQ), quality score (>5 or $\leq 5$), OR/HR/RR adjusted for age (yes or no), gender (yes or no), smoking (yes or no), drinking (yes or no), and BMI (yes or no), respectively. In addition, sensitivity analyses were also performed to explore the potential study, which greatly affected the robustness of the result. Due to different definitions of exposure categories in separate studies, a fixed-effect dose–response analysis was performed to quantitatively estimate the potential association between the increment per day for dietary vitamin E intake and the esophageal cancer risk. We recalculated the pooled OR of esophageal cancer for every 3 mg/day increment of dietary vitamin E intake through previously described methods [19,20]. Furthermore, a non-linear dose–response analysis was likewise performed by using restricted cubic splines with three knots at fixed percentiles (10%, 30% and 50%) of the distribution of exposure [21,22]. We calculated the overall $p$-value by testing that the two regression coefficients were simultaneously equal to zero. We also calculated $p$-values for non-linearity by testing that the coefficient of the second spline was equivalent to zero. The details of this method have been cited previously [23,24].

The aforementioned method involves the following items: (1) the number of cases and person-years or non-cases and the RRs or ORs with the variance estimates for at least three quantitative exposure categories; and (2) the median or mean level of these exposures in each category (if ranges was reported, mean levels were calculated by averaging the lower and upper boundary; if the lower boundary of the lowest category was not reported, we set zero as the lower boundary; if the upper boundary of the highest category was not reported, we added the same amplitude with the closest category to the lower boundary as the upper boundary) [25,26].

Finally, Egger’s and Begg’s test were performed to assess the potential publication bias. If both of $p$ values for Egger’s test and Begg’s test were less than 0.05 ($p < 0.05$), it indicated the publication bias existed [27]. If the publication bias existed, we used the “trim and fill” method to add the potentially missing studies for adjustment for the funnel plot’s asymmetry [28,29], and observed the variation of pooled OR (95% CI). If the pooled OR (95% CI) changed weakly or remained unchanged, it indicated that the result was robust. All the statistical analyses were performed by using Stata 11.2 software (Stata Corp Lakeway Drive, College Station, TX, USA), and a two-sided $p$ value $< 0.05$ was considered statistically significant.

3. Results

3.1. Literature Search, Study Characteristics, and Quality Assessment

A total of 599 articles, 256 articles, 123 articles, and 29 articles were obtained from EMBASE, PubMed, the Web of Science, and the Cochrane Library, respectively. After removing 278 duplicate
studies, 729 articles remained for viewing the titles and abstracts, and then 42 articles remained for review of the full text for eligibility. Among them, three articles reported vitamin E supplementation but did not report dietary vitamin E intake in relation to esophageal cancer, one article reported vitamin E intake from diet plus supplements, two articles reported the correlation between dietary α-tocopherol intake and esophageal cancer, one article reported serum vitamin E level in relation to esophageal cancer, three articles reported combination nutrients in relation to esophageal cancer, two articles reported vitamin E intake and upper digestive tract cancer, one article was an animal study, one article was published in German, six articles did not report OR/HR/RR or 95% CI, 11 studies were reviews, and one article was a cross-sectional study. Besides, two additional articles were obtained by screening the lists of references [9,30]. Finally, 12 articles reported 14 studies involving 3013 cases and 11,384 non-cases were selected for the meta-analysis [8–14,30–34]. The detailed processes of screening articles are presented in Figure 1.

Figure 1. Flow chart of the electronic search for eligible articles. OR: odds ratio; HR: hazard ratio; RR: relative risk; CI: confidence interval.

Among these articles, one article was a cohort study [34] and 11 articles were case-control studies [8–14,30–33] in the meta-analysis. These studies were conducted in Europe [9,10,14,31,33,34], America [13,30,32], Asia [11,12], and Oceania [8]. Dietary vitamin E intakes were assessed by a validated food frequency questionnaire (FFQ) [8–14,30], which was more applicable than the unvalidated FFQ [31–34]. The identification of esophageal cancer cases was based on cancer registries [9,13,30] and the pathological diagnoses [8,10–12,14,31–34]. The detailed characteristics of included studies are presented in Table 1. For the quality assessment of the included studies, four articles involving five studies were granted for points ≤5 [31–34], eight articles involving nine studies were given points >10 [8–14,30], and details of the quality assessment are presented in Supplementary Tables S1 and S2.
Table 1. Characteristics of included studies on the association between dietary vitamin E intake and esophageal cancer.

| Study Period | Country, Source of Case/Non-Case | Method of Identifying Case, the Number of Case/Non-Case | Methods of Dietary Vitamin E Intake Assessment | OR/HR/RR (95% CI) for Highest vs. Lowest Dietary Vitamin E Intake | Adjustment for Confounders |
|--------------|---------------------------------|--------------------------------------------------------|----------------------------------------------|---------------------------------------------------------------|-----------------------------|
| 1992–1994    | France, population-based case-control | Pathological diagnoses, 243/393 | Validated-FFQ-350 items | 0.84 (0.48, 1.47) for EAC | Age, gender, BMI, energy intake, smoking, occupation, alcohol, NSAID use, age, sex, gastroesophageal reflux disease symptoms, BMI, smoking, physical activity, education |
| 1996–1997    | Uruguay, hospital-based case-control | Pathological diagnoses, 232/393 | Validated-FFQ-350 items | 0.50 (0.30, 0.70) for mixed subtype a | Age, sex, residence, urban/rural status, education, BMI, smoking, alcohol and energy intake |
| 2001–2004    | Mexico, hospital-based case-control | Cancer registries, 224/393 | Validated-FFQ-350 items | 0.58 (0.40, 0.85) for mixed subtype a | Age, gender, education, BMI, energy intake, smoking, alcohol, family history of cancer |
| 1992–1994    | Mexico, population-based case-control | Cancer registries, 224/393 | Validated-FFQ-350 items | 1.00 (0.60, 1.90) for EAC | Age, gender, education, BMI, smoking, alcohol, and energy intake |
| 1996–1997    | France, hospital-based case-control | Pathological diagnoses, 208/393 | Non-validated-FFQ-350 items | 0.48 (0.30, 0.74) for EAC | Age, sex, gastroesophageal reflux disease symptoms, BMI, smoking, physical activity, education |
| 1996–1999    | Mexico, population-based case-control | Cancer registries, 224/393 | Validated-FFQ-350 items | 0.11 (0.03, 0.74) for ESCC | Age, sex, gastroesophageal reflux disease symptoms, BMI, smoking, physical activity, education |
| 1992–1997    | Ireland, population-based case-control | Pathological diagnoses, 224/393 | Validated-FFQ-350 items | 0.40 (0.30, 0.70) for ESCC | Age, gender, smoking, alcohol and energy intake |
| 1999–2000    | Italy, hospital-based case-control | Pathological diagnoses, 304/743 | Validated-FFQ-78 items | 0.27 (0.12, 0.45) for mixed subtype a | Age, gender, alcohol and smoking |
| 1991–1994    | Brazilian, population-based case-control | Cancer registries, 743/1975 | Validated-FFQ-40 items | 0.70 (0.48, 1.01) for EAC | Age, gender, smoking, alcohol and energy intake |
| 1992–1997    | Mexico, hospital-based case-control | Pathological diagnoses, 350/743 | Validated-FFQ-125 items | 0.84 (0.48, 1.47) for EAC | Age, gender, smoking, alcohol and energy intake |
| 1996–1997    | Mexico, hospital-based case-control | Cancer registries, 350/743 | Validated-FFQ-125 items | 0.50 (0.30, 0.70) for mixed subtype a | Age, sex, residence, urban/rural status, education, BMI, smoking, alcohol and energy intake |
| 1992–1997    | France, hospital-based case-control | Pathological diagnoses, 350/743 | Validated-FFQ-125 items | 0.58 (0.40, 0.85) for mixed subtype a | Age, gender, education, BMI, energy intake, smoking, alcohol, family history of cancer |
| 1992–1994    | France, hospital-based case-control | Pathological diagnoses, 193/809 | Non-validated-FFQ-39 items | 0.48 (0.30, 0.74) for EAC | Age, sex, gastroesophageal reflux disease symptoms, BMI, smoking, physical activity, education |

EAC: esophagus adenocarcinoma; FFQ: food frequency questionnaire; OR: odds ratio; BMI: body mass index; NSAID: nonsteroidal anti-inflammatory drug; NA: not applied; ESCC: esophageal squamous cell carcinoma; RR: relative risk; H pylori: Helicobacter pylori; PUFA: polyunsaturated fatty acid; SFA: saturated fatty acids; FR: hazard ratio; a mixed subtype: did not report specific subtype; b this study did not report the ORs (95% CI) of ESCC and EAC for the highest vs. lowest category of dietary vitamin E intake, so we recalculated the ORs (95% CI) based on usable data; c did not report the number of the items.
3.2. Meta-Analysis of Dietary Vitamin E Intake and the Esophageal Cancer Risk

Twelve articles involving 14 studies on dietary vitamin E intake and the esophageal cancer risk were included in this meta-analysis. The pooled OR of the esophageal cancer risk for the highest vs. lowest intake of dietary vitamin E was calculated. In a comprehensive analysis, we found that dietary vitamin E intake was inversely associated with the esophageal cancer risk (OR = 0.47, 95% CI: 0.36–0.60) with significant heterogeneity ($I^2 = 67.5\% ; p < 0.001$) (Figure 2, Table 2).

Figure 2. The forest plot for the meta-analysis on dietary vitamin E intake and the esophageal cancer risk. ESCC: esophageal squamous cell carcinoma; EAC: esophageal adenocarcinoma; mixed subtype: did not report the specific subtype of esophageal cancer.

Table 2. Overall and subgroup analysis of the association between dietary vitamin E intake and the risk of esophageal cancer.

| Outcome of Interest          | No. of Studies | No. of Cases/Non-Cases | ORs (95% CIs) | $p$ for Test | $I^2$ (%) | $p_{het}$ |
|------------------------------|----------------|------------------------|---------------|-------------|-----------|-----------|
| Dietary Vitamin E           | 14             | 3013/11,384            | 0.47 (0.36, 0.6) | <0.001      | 67.5      | <0.001    |
| Pathological type           |                |                        |               |             |           |           |
| EAC                          | 6              | 1037/6661              | 0.66 (0.49, 0.88) | 0.005       | 53.5      | 0.057     |
| ESCC                         | 5              | 817/1975               | 0.29 (0.18, 0.44) | <0.001      | 43.4      | 0.133     |
| Mixed subtype *              | 3              | 1159/2748              | 0.46 (0.32, 0.68) | <0.001      | 48.7      | 0.142     |
| Geographic location          |                |                        |               |             |           |           |
| Europe                       | 7              | 1639/7185              | 0.37 (0.23, 0.60) | <0.001      | 73.9      | 0.001     |
| America                      | 4              | 678/2216               | 0.60 (0.41, 0.88) | 0.008       | 65.8      | 0.032     |
| Others †                    | 3              | 696/1983               | 0.44 (0.27, 0.73) | 0.001       | 55.0      | 0.108     |
| Study design                 |                |                        |               |             |           |           |
| Case-control                 | 13             | 2952/7672              | 0.44 (0.37, 0.58) | <0.001      | 68.0      | <0.001    |
| Cohort                       | 1              | 61/3712                | 0.7 (0.48, 1.02) | 0.06        | NA        | NA        |
| Source of control           |                |                        |               |             |           |           |
| Population                   | 9              | 2038/9373              | 0.51 (0.36, 0.71) | <0.001      | 70.3      | 0.001     |
| Hospital                     | 5              | 975/2011               | 0.40 (0.28, 0.58) | <0.001      | 57.1      | 0.054     |
| Sample size                  |                |                        |               |             |           |           |
| <500                         | 6              | 497/4557               | 0.43 (0.25, 0.72) | 0.002       | 68.5      | 0.007     |
| ≥500                         | 8              | 2516/6827              | 0.47 (0.35, 0.63) | <0.001      | 70.3      | 0.001     |
| Method of case identified    |                |                        |               |             |           |           |
| Pathological diagnoses       | 10             | 1658/7586              | 0.44 (0.32, 0.59) | <0.001      | 63.3      | 0.004     |
| Cancer registries            | 4              | 1355/3798              | 0.53 (0.32, 0.9)  | 0.02        | 78.2      | 0.003     |
3.3. Meta-Regression and Subgroup Analysis

Since significant heterogeneity was found in this meta-analysis; meta-regression and subgroup analysis were performed to explore the source of the between-study heterogeneity. Meta-regression analysis found adjustment for variables like age (p = 0.044), gender (p = 0.017), smoking (p = 0.044), and BMI (p = 0.017) was the possible source of the heterogeneity. The following covariance such as geographical distribution (p = 0.475), study type (p = 0.403), source of control (p = 0.433), sample size (p = 0.821), pathological type (p = 0.072), the method of identifying esophageal cancer cases (p = 0.463), dietary vitamin E assessment method (p = 0.394), quality score (p = 0.355), and adjustment for drinking (p = 0.261) did not explain the between-study heterogeneity.

In the subgroup analysis, when stratified by adjustment for variables like age, gender, smoking, and BMI, no statistical heterogeneity was found in the studies without adjustment for variables like age (I² = 0.0%, p = 0.398), gender (I² = 0.0%, p = 0.556), smoking (I² = 0.0%, p = 0.398), and BMI (I² = 0.0%, p = 0.556). When controlled by pathological type, heterogeneity decreased in the EAC cases (I² = 53.3%, p = 0.057), ESCC cases (I² = 43.3%, p = 0.133), and mixed subtype cases (I² = 48.7%, p = 0.142). In general, in the cases with the highest vs. the lowest category of the dietary vitamin E intake, dietary vitamin E has a rather inverse association with both the risk of EAC (OR = 0.66, 95% CI: 0.49–0.88) and the risk of ESCC (OR = 0.29, 95% CI: 0.18–0.44). The detailed results on subgroup analysis are shown in Table 2.

3.4. Sensitivity Analysis, Publication Bias Analysis, and Trim and Fill Analysis

A total of four articles reporting five studies involving 970 cases and 2225 non-cases [2,8,14,33] were included in the dose–response analyses based on the relevant criteria mentioned in the method of statistical analysis. Among the four articles [2,8,14,33], the dietary vitamin E intake per day was defined mg/day, except for Murphy’s article [14], which was defined intake in µg/day. Therefore,
we turned the μg/day to mg/day by dividing 1000. Overall analysis, no heterogeneity was found ($p = 0.987$), no significant non-linear dose–response relationship was found (non-linearity = 0.864), but a marginally linear dose–response relationship was found for 3 mg/day increment of dietary vitamin E intake and the risk of esophageal cancer (OR = 0.78, 95% CI: 0.57–1.06, plinearity = 0.114) (Figure 3A). For the sensitivity analysis, no one specific study significantly affected the pooled OR (95% CI) (Supplementary Figure S1). Both Egger’s test and Begg’s test found publication bias existed ($p = 0.008$, and $p = 0.005$, respectively). Then, trim and fill analysis was performed for the adjustment of funnel plot asymmetry; no missing studies were added and the adjusted OR was 0.47 (95% CI: 0.36–0.60), which showed the pooled OR (95% CI) remained unchanged. The funnel plot of trim and fill analysis was shown in Figure 3B.

**Figure 3.** (A) The dose-response analyses for the association between dietary vitamin E intake and the esophageal cancer risk. The solid line and the long dash line represent the pooled OR and corresponding 95% CI. The short dash line represents the linear association; (B) The funnel plot with trim and fill analysis for studies on the association between dietary vitamin E intake and the esophageal cancer risk.

4. Discussion

Up to now, epidemiology studies have provided ambiguous evidences for the relationship between dietary vitamin E intake and the esophageal cancer risk. To solve the divergence, we performed a meta-analysis on the association between dietary vitamin E intake and esophageal cancer risk (including EAC and ESCC). We found that the higher dietary vitamin E intake was related to a lower esophageal cancer risk, especially for ESCC. The aforementioned findings were in line with many other studies of dietary vitamin E intake and various cancer risks. One published dose–response meta-analysis has suggested that bladder cancer risk decreased by 17% for every 10 mg/day increase of dietary vitamin E intake (RR = 0.83, 95% CI: 0.72–0.95) [35]. Another meta-analysis focused on the association between dietary antioxidant vitamins intake and gastric cancer, which showed the higher dietary vitamin E intake decreased the risk of gastric cancer by 35% (OR = 0.65, 95% CI: 0.57–0.74), and the gastric cancer risk decreased by 21% for every 15 mg/day increase of dietary vitamin E intake (OR = 0.79, 95% CI: 0.66–0.94) [36]. The findings of one latest meta-analysis containing 11 studies (10 prospective studies and one case–control study) also showed that the dietary vitamin E intake was inversely associated with the risk of lung cancer (RR = 0.86, 95% CI: 0.74–0.99) [37]. The findings of one recent meta-analysis containing 11 studies (10 prospective studies and one case–control study) also showed that the dietary vitamin E intake was inversely associated with the risk of lung cancer (RR = 0.86, 95% CI: 0.74–0.99) [37]. Therefore, the combination of the meta-analyses mentioned above and our study further suggested that dietary vitamin E intake was inversely associated with many cancer risks, which might provide relevant population-based evidence for vitamin E preventing tumorigenesis, including in esophageal cancer.

In 2007, Kubo’s meta-analysis explored the association between antioxidant intake (including vitamin E) and the risk of esophageal and gastric cardia adenocarcinoma, and showed a marginally
inverse association between vitamin E intake and EAC risk (OR = 0.80, 95% CI: 0.63–1.03), but did not report the relationship between vitamin E intake and ESCC risk [38]. In Kubo’s research, a total of three case–control studies on the association between vitamin E intake and the EAC risk were included, two of which were on dietary vitamin E intake and the EAC risk and one of which was on dietary α-tocopherol and EAC risk. α-tocopherol is one of vitamin E’s homologues, but we mainly take in total vitamin E not just α-tocopherol from various foods such as cereal grains, nuts, particularly vegetable oils [39]. The dietary vitamin E intake was calculated by using the following formulas that came from the literature of Yang Yue et al. [40]: \( \alpha\text{-tocopherol equivalent (\(\alpha\text{-TE, mg}) = 1.0 \times \alpha\text{-tocopherol (mg)} + 0.5 \times \beta\text{-tocopherol (mg)} + 0.1 \times \gamma\text{-tocopherol (mg)} + 0.02 \times \delta\text{-tocopherol (mg)} + 0.3 \times \alpha\text{-tocotrienols}, \) or “vitamin E (mg) = \alpha\text{-tocopherol (mg)} + (\beta + \gamma)\text{-tocopherol (mg)} + \delta\text{-tocopherol (mg)}” [41]. Importantly, dietary α-tocopherol intake is not equivalent to dietary vitamin E intake. Therefore, Carman’s and Terry’s studies were excluded in our meta-analysis because of only reporting dietary α-tocopherol intake [40,42].

The present meta-analysis showed that higher vitamin E intake is negatively associated with the risk of esophageal cancer. This may be explained by the strong oxidative properties of vitamin E [43,44]. One previous study showed that vitamin E could inhibit DNA oxidative damage and lipid peroxidation by reducing the level of endogenous reactive oxygen species, and thereby prevented gene mutations as well as tumor formation [45]. Additionally, in N-nitrosomethylbenzylamine (NMBZA)-treated rats, 8OH-dG was significantly increased in various esophageal lesions, whereas early continuous supplementation of vitamin E reduced 8OH-dG in each category of lesions [46]. In vivo, vitamin E may also suppress NMBZA-induced carcinogenesis in rat esophagus by blocking activation of nuclear factor-kappa B (NF\(\kappa\)B) and abnormal metabolic pathway of arachidonic acid [47].

Based on the results of meta-regression and subgroup analysis, we found that the possible sources of between-study heterogeneity for this meta-analysis were adjustment for variables like age, gender, smoking, and BMI. As we know, the incidence of esophageal cancer increases with age, and the incidence of esophageal cancer worldwide in males is more than double that in females (2.4:1). Furthermore, one meta-analysis of 12 studies showed that about 68% esophageal cancer cases were attributed to smoking (RR = 3.01, 95% CI: 2.30–3.94) [48]. As for BMI, it was widely used for determining obesity and overweight. When the dose increased by per 5 kg/m\(^2\) for BMI, the esophageal cancer risk was enhanced by approximately 10% (RR = 1.11, 95% CI: 1.09–1.14) [49,50]. The aforementioned findings may respectively explain the reasons for adjustment for variables like age, gender, smoking, and BMI as the potential sources of heterogeneity for this meta-analysis. Besides, when stratified by pathological type, we found the heterogeneity was reduced, which revealed that pathological type was also the potential source of heterogeneity. The higher dietary vitamin E intake has a negative correlation with the risk of ESCC, which were more than the negative correlation double those for the EAC risk.

To our knowledge, the present meta-analysis had several advantages. Firstly, the study was a quantitative and comprehensive dose–response analysis to evaluate the association between dietary vitamin E intake and the risk of esophageal cancer. Secondly, meta-regression and subgroup analysis were simultaneously performed to explore the potential sources of heterogeneity. Thirdly, sensitive analysis found no one specific study significantly affected the pooled OR (95% CI). Fourthly, trim and fill analysis did not find potentially missing articles, and the pooled OR (95% CI) was maintained after the adjustment of the asymmetry of the funnel plot, which revealed that our findings might be robust and sound.

However, several limitations should also be taken into consideration. Firstly, most of the eligible studies were case–control studies, which were prone to cause recall bias and selection bias. Secondly, dietary vitamin E intakes were assessed by validated FFQs [8–14,30], and dietary vitamin E intakes were assessed by unvalidated FFQs [31–34]. The former was more applicable than the latter, and 33% articles used not-validated FFQ, which might affect the estimation of the dietary vitamin E intake. Thirdly, only a few studies were included in the dose–response analysis, and the corresponding sample
size was small. Therefore, the association between the increase of per day dietary vitamin E intake and the esophageal cancer risk should be explored by using more usable data in the future investigation. Last but not least, there was a higher mortality rate for esophageal cancer in Eastern Asia according to the data from GLOBOCAN 2012, but most studies were conducted in Europe and America, and only few studies were performed in Asia. This may induce regional restrictions to the findings, and they may not be generalized to Asian population very well. Therefore, studies on dietary vitamin E and esophageal cancer research should be expanded, especially in areas with high incidence of esophageal cancer, such as in the Asian region. The association between dietary vitamin E intake and esophageal cancer risk should be researched in more areas worldwide.

5. Conclusions

In summary, our study suggests that dietary vitamin E intake is inversely associated with the esophageal cancer risk. Considering the limitations of the included studies, more large-scale prospective studies and randomized controlled trials are still needed to confirm our results, though our findings could provide certain evidence for esophageal cancer prevention.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/7/801/s1. Figure S1: The sensitive analyses for studies on the association between dietary vitamin E intake and the esophageal cancer risk. Table S1: Methodological quality of case-control studies included in the meta-analysis, Table S2: Methodological quality of prospective studies included in the meta-analysis.

Author Contributions: L.C. designed the study; L.C., L.L and Y.T. assessed studies for inclusion, extracted data, and assessed validity; L.C. and L.L. and conducted meta-analyses; F.X. and T.Q. tabulated data; L.C. wrote the first draft of the manuscript; L.L. and F.X. provided critical review of the manuscript.

Funding: National Natural Science Fund: 81402670&81573151.

Acknowledgments: This work was supported by the project of National Natural Science Fund (81402670), and the project of National Natural Science Fund (81573151).

Conflicts of Interest: The authors declare no competing financial interests.

References

1. Torre, L.A.; Bray, F.; Siegel, R.L.; Joannie Lortet-Tieulent, J.; Jemal, A. Global Cancer Statistic, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
2. Schmassmann, A.; Oldendorf, M.G.; Gebbers, J.O. Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007. Eur. J. Epidemiol. 2009, 24, 603–609. [CrossRef] [PubMed]
3. Zhang, Y. Epidemiology of esophageal cancer. World J. Gastroenterol. 2013, 19, 5598–5606. [CrossRef] [PubMed]
4. Yates, M.; Cheong, E.; Luben, R.; Igali, L.; Fitzgerald, R.; Khaw, K.T.; Hart, A. Body mass index, smoking, and alcohol and risks of barrett’s esophagus and esophageal adenocarcinoma: A UK prospective cohort study. Dig. Dis. Sci. 2014, 59, 1552–1559. [CrossRef] [PubMed]
5. Barve, A.; Khor, T.O.; Nair, S.; Reuhl, K.; Suh, N.; Reddy, B.; Newmark, H.; Kong, A.N. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer 2009, 124, 1693–1699. [CrossRef] [PubMed]
6. Das Gupta, S.; Suh, N. Tocopherols in cancer: An update. Mol. Nutr. Food Res. 2016, 60, 1354–1363. [CrossRef] [PubMed]
7. Huang, H.; He, Y.; Cui, X.X.; Goodin, S.; Wang, H.; Du, Z.Y.; Li, D.; Zhang, K.; Tony Kong, A.N.; DiPaola, R.S.; et al. Potent inhibitory effect of δ-tocopherol on prostate cancer cells cultured in vitro and grown as xenograft tumors in vivo. J. Agric. Food Chem. 2014, 62, 10752–10758.
8. Ibiebele, T.I.; Hughes, M.C.; Nagle, C.M.; Bain, C.J.; Whiteman, D.C.; Webb, PM. Study of Digestive Health and Australian Cancer Study. Dietary antioxidants and risk of Barrett’s esophagus and adenocarcinoma of the esophagus in an Australian population. Int. J. Cancer 2013, 133, 214–224. [CrossRef] [PubMed]
9. Tuyns, A.J.; Riboli, E.; Doornbos, G.; Péquignot, G. Diet and esophageal cancer in Calvados (France). Nutr. Cancer 1987, 9, 81–92. [CrossRef] [PubMed]
10. Franceschi, S.; Bidoli, E.; Negri, E.; Zambon, P.; Talamini, R.; Ruol, A.; Parpinel, M.; Levi, F.; Simonato, L.; La Vecchia, C. Role of macronutrients, vitamins and minerals in the aetiology of squamous-cell carcinoma of the oesophagus. Int. J. Cancer 2015, 86, 626–631. [CrossRef] [PubMed]

11. Jessri, M.; Rashidkhani, B.; Hajizadeh, B.; Jessri, M.; Gotay, C. Macronutrients, vitamins and minerals intake and risk of esophageal squamous cell carcinoma: A case-control study in Iran. Nutr. J. 2011, 10, 137. [CrossRef] [PubMed]

12. Tang, L.; Lee, A.H.; Xu, F.; Zhang, T.; Lei, J.; Binns, C.W. Fruit and vegetable consumption and risk of esophageal cancer: A case-control study in north-west China. Dis. Esophagus 2014, 27, 777–782. [CrossRef] [PubMed]

13. Chen, H.; Tucker, K.L.; Graubard, B.I.; Heineman, E.F.; Markin, R.S.; Potischman, N.A.; Russell, R.M.; Weissenburger, D.D.; Ward, M.H. Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr. Cancer 2002, 42, 33–40. [CrossRef] [PubMed]

14. Murphy, S.J.; Anderson, L.A.; Ferguson, H.R.; Johnston, B.T.; Watson, P.R.; McGuigan, J.; Comber, H.; Reynolds, J.V.; Murray, I.J.; Cantwell, M.M. Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett’s esophagus. J. Nutr. 2010, 140, 1757–1763. [CrossRef] [PubMed]

15. Gläucia, F.C.; Marcos, R.D.S.; Tatiani, O.F.; Priscla, S.S.; Thais, K.A.; Ana, R. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies Meta-Analyses; Ottawa Hospital Research Institute: Ottawa, ON, Canada, 2013.

16. Greenland, S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 1987, 9, 1–30. [CrossRef] [PubMed]

17. Cui, L.; Liu, X.; Tian, Y.; Xie, C.; Li, Q.; Cui, H.; Sun, C. Flavonoids, flavonoid subclasses, and esophageal cancer risk: A meta-analysis of epidemiologic studies. Nutrients 2016, 8, 350. [CrossRef] [PubMed]

18. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22, 719–748. [PubMed]

19. Studies, M.O.P. Association of fibrinogen, c-reactive protein, albumin, or leukocyte count with coronary heart disease. J. Am. Med. Assoc. 1998, 279, 1477–1482.

20. Chêne, G.; Thompson, S.G. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am. J. Epidemiol. 1996, 144, 610–621. [CrossRef] [PubMed]

21. Greenland, S.; Longnecker, M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am. J. Epidemiol. 1992, 135, 1301–1309. [CrossRef] [PubMed]

22. Jiang, L.; Hou, R.; Gong, T.T.; Wu, Q.J. Dietary fat intake and endometrial cancer risk: Dose-response meta-analysis of epidemiological studies. Sci. Rep. 2015, 5. [CrossRef] [PubMed]

23. Bagnardi, V.; Zambon, A.; Quatto, P.; Corrao, G. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am. J. Epidemiol. 2004, 159, 1077–1086. [CrossRef] [PubMed]

24. Royston, P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat. Med. 2000, 19, 1831–1847. [CrossRef]

25. Hong, Z.; Tian, C.; Zhang, X. Dietary calcium intake, vitamin D levels, and breast cancer risk: A dose-response analysis of observational studies. Breast Cancer Res. Treat. 2012, 136, 309–312. [CrossRef] [PubMed]

26. Wu, W.; Kang, S.; Zhang, D. Association of vitamin B6, vitamin B12 and methionine with risk of breast cancer: A dose—response meta-analysis. Br. J. Cancer 2013, 109, 1926–1944. [CrossRef] [PubMed]

27. Song, F.; Gilbody, S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. Plant Physiol. 1998, 116, 469–477.

28. Duval, S.; Tweedie, R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J. Am. Stat. Assoc. 2000, 95, 89–98.

29. Duval, S.; Tweedie, R. Trim and fill: A simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56, 455–463. [CrossRef] [PubMed]

30. Mayne, S.T.; Risch, H.A.; Dubrow, R.; Chow, W.H.; Gammon, M.D.; Vaughan, T.L.; Farrow, D.C.; Schoenberg, J.B.; Stanford, J.L.; Ahsan, H.; et al. Nutrient Intake and Risk of Subtypes of Esophageal and Gastric Cancer; American Association for Cancer Research: Philadelphia, PA, USA, 2001.

31. Launoy, G.; Milan, C.; Day, N.; Pienkowski, M.P.; Gignoux, M.; Faire, J. Diet and squamous-cell cancer of the oesophagus: A French multicentre case-control study. Int. J. Cancer 1998, 76, 7–12. [CrossRef]
32. De Stefani, E.; Ronco, A.; Mendilaharsu, M.; Deneo-Pellegrini, H. Diet and risk of cancer of the upper aerodigestive tract—II. Nutrients. Oral Oncol. 1999, 35, 22–26. [CrossRef]
33. Bollschweiler, E.; Wolfgarten, E.; Nowroth, T.; Rosendahl, U.; Mönig, S.P.; Hölscher, A.H. Vitamin intake and risk of subtypes of esophageal cancer in Germany. J. Cancer Res. Clin. Oncol. 2002, 128, 575–580. [CrossRef] [PubMed]
34. Kang, J.; Yates, M.; Luben, R.; Cheong, E.; Alexandre, L.; Lgali, L.; Khaw, K.T.; Hart, A. OC-038 The age-dependent relationship of dietary antioxidant intake and the risk of Barrett’s oesophagus and oesophageal adenocarcinoma: A UK prospective cohort study using micronutrient data from food diaries and serum biomarkers. Gut 2015, 64. [CrossRef]
35. Chen, F.; Li, Q.; Yang, Y.; Yang, W.; Shi, F.; Qu, Y. Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: A dose-response meta-analysis. Sci. Rep. 2015, 5, 9599. [CrossRef] [PubMed]
36. Li, P.; Zhang, H.; Chen, J.; Shi, Y.; Cai, J.; Yang, J.; Wu, Y. Association between dietary antioxidant vitamins intake/blood level and risk of gastric cancer. Int. J. Cancer 2014, 135, 1444–1453. [CrossRef] [PubMed]
37. Chen, G.; Wang, J.; Hong, X.; Chai, Z.; Li, Q. Dietary vitamin E intake could reduce the risk of lung cancer: Evidence from a meta-analysis. Int. J. Clin. Exp. Med. 2015, 8, 6631–6637. [PubMed]
38. Kubo, A.; Corley, D.A. Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am. J. Gastroenterol. 2007, 102, 2323–2330. [CrossRef] [PubMed]
39. Yang, T.C.; Duthie, G.G.; Aucott, L.S.; Macdonald, H.M. Vitamin E homologues α- and γ-tocopherol are not associated with bone turnover markers or bone mineral density in peri-menopausal and post-menopausal women. Osteoporosis Int. 2016, 27, 2281–2290. [CrossRef] [PubMed]
40. Carman, S.; Kamangar, F.; Freedman, N.D.; Wright, M.E.; Dawsey, S.M.; Dixon, L.B.; Subar, A.; Schatzkin, A.; Ahn, J.C. Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP diet and health study. Int. J. Cancer 2009, 125, 165–170. [CrossRef] [PubMed]
41. Yang, Y.; Wang, G.; Pan, X. China Food Composition; Peking University Medical Press: Beijing, China, 2009.
42. Terry, P.; Lagergren, J.; Ye, W.; Nyren, O.; Wolk, A. Antioxidants and cancers of the esophagus and gastric cardia. Int. J. Cancer 2000, 87, 750–754. [CrossRef] [PubMed]
43. Clark, L.C.; Dalkin, B.; Krongrad, A.; Combs, G.F., Jr.; Turnbull, B.W.; Slate, E.H.; Witherington, R.; Herlong, J.H.; Janosko, E.; Carpenter, D.; et al. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br. J. Urol. 1998, 81, 730–734. [CrossRef] [PubMed]
44. Klein, E.A. The Selenium and Vitamin E Cancer Prevention Trial; Humana Press: Clifton County, NJ, USA, 2009.
45. Bartsch, H.; Nair, J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: Role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 2006, 391, 499–510. [CrossRef] [PubMed]
46. Yang, H.; Fang, J.; Jia, X.; Han, C.; Chen, X.; Yang, C.S.; Li, N. Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet. Carcinogenesis 2011, 32, 381–388. [CrossRef] [PubMed]
47. Hui, Y.; Jia, X.; Chen, X.; Yang, C.S.; Li, N. Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: The possible role of nuclear factor kappaB signaling pathway. Int. J. Cancer 2012, 131, 1517–1527.
48. Ose, I.; Matsuo, K.; Ito, H.; Wakai, K.; Nagata, C.; Mizoue, T.; Tanaka, K.; Tsuji, I.; Tamakoshi, A.; Sasazuki, S.; et al. Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Cigarette smoking and esophageal cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn. J. Clin. Oncol. 2012, 42, 63–73. [CrossRef] [PubMed]
49. Ai, K.; Corley, D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: A systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 2006, 15, 872–878.
50. Olsen, C.M.; Pandeya, N.; Green, A.C.; Webb, P.M.; Whiteman, D.C. Australian Cancer Study. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am. J. Epidemiol. 2011, 174, 582–590. [CrossRef] [PubMed]